Stockscreener 앱 받기
27.27
0.69%
-0.19
전일 마감가:
$27.46
열려 있는:
$27.52
하루 거래량:
1.18M
Relative Volume:
0.99
시가총액:
$1.59B
수익:
$32.87M
순이익/손실:
$674.31M
주가수익비율:
2.4005
EPS:
11.36
순현금흐름:
$-330.11M
1주 성능:
-1.66%
1개월 성능:
-37.50%
6개월 성능:
-20.96%
1년 성능:
-28.56%
1일 변동 폭
$26.78
$27.66
1주일 범위
$26.78
$28.61
52주 변동 폭
$22.24
$46.00
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
명칭
Agios Pharmaceuticals Inc
전화
617-649-8600
주소
88 SIDNEY STREET, CAMBRIDGE, MA
AGIO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
27.27 | 1.60B | 32.87M | 674.31M | -330.11M | 11.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-24 | 개시 | Truist | Buy |
| 2025-11-20 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-11-19 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-24 | 개시 | H.C. Wainwright | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-09-27 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-02-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-02-03 | 개시 | Piper Sandler | Overweight |
| 2022-11-17 | 업그레이드 | Goldman | Sell → Neutral |
| 2022-07-27 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2021-12-03 | 개시 | BofA Securities | Buy |
| 2021-07-30 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-07-01 | 개시 | Raymond James | Mkt Perform |
| 2021-06-10 | 개시 | H.C. Wainwright | Buy |
| 2021-03-01 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-03-01 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2021-02-26 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-10-22 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2020-03-04 | 개시 | Barclays | Equal Weight |
| 2019-11-26 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-09-23 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-05-23 | 재개 | Goldman | Neutral |
| 2019-02-15 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2018-09-25 | 개시 | Leerink Partners | Mkt Perform |
| 2018-05-23 | 개시 | Citigroup | Buy |
| 2018-04-11 | 재확인 | Credit Suisse | Outperform |
| 2018-02-15 | 재확인 | Needham | Buy |
| 2018-02-15 | 재확인 | SunTrust | Buy |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2017-08-10 | 재확인 | Needham | Buy |
| 2017-08-08 | 재확인 | SunTrust | Buy |
| 2017-08-02 | 업그레이드 | Leerink Partners | Mkt Perform → Outperform |
| 2017-06-26 | 다운그레이드 | Janney | Buy → Neutral |
| 2017-01-17 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2016-10-24 | 개시 | Needham | Buy |
| 2016-06-13 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2016-05-18 | 재확인 | SunTrust | Buy |
모두보기
Agios Pharmaceuticals Inc 주식(AGIO)의 최신 뉴스
Frazier Life Sciences Management L.P. Increases Stock Position in Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Agios Pharmaceuticals, Inc. $AGIO Shares Purchased by Bellevue Group AG - MarketBeat
Agios Pharmaceuticals, Inc. $AGIO Position Boosted by Boothbay Fund Management LLC - MarketBeat
Levi & Korsinsky Announces an Investigation on Behalf of Agios Pharmaceuticals, Inc. (AGIO) Shareholders Who May Have Been Affected by Fraud - ACCESS Newswire
Is Agios Pharmaceuticals Inc 8AP a good long term investmentSell Signals and Alerts & Learn From the Strategies of Institutions - earlytimes.in
Agios Pharmaceuticals, Inc. (AGIO) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights - ACCESS Newswire
Levi & Korsinsky Reminds Agios Pharmaceuticals, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities LawsAGIO - ACCESS Newswire
Agios Awaits Pyrukynd Decision in Thalassemia as FDA Misses Due Date - The Globe and Mail
Agios Pharma stock awaits FDA decision on Pyrukynd as PDUFA date passes - Investing.com Canada
AGIO STOCK ALERT: Levi & Korsinsky Notifies Agios Pharmaceuticals, Inc. Investors of an Ongoing Investigation - ACCESS Newswire
Marshall Wace LLP Purchases 163,796 Shares of Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Agios Pharmaceuticals' Supplemental NDA for Mitapivat to Treat Thalassemia Still Under FDA Review - marketscreener.com
Agios shares slide after FDA misses decision deadline on mitapivat application - MSN
Agios Pharmaceuticals (AGIO) Awaits FDA Decision on Mitapivat Ap - GuruFocus
Agios Pharmaceuticals says FDA has not issued decision on Agios' sNDA for mitapivat - marketscreener.com
FDA delays decision on Agios’ thalassemia drug application By Investing.com - Investing.com Canada
Agios Pharma falls after FDA misses decision deadline on blood-disorder drug filing - TradingView — Track All Markets
Agios Pharmaceuticals Provides Update on FDA Review Status for Supplemental New Drug Application of Mitapivat for Thalassemia - Quiver Quantitative
Agios stock falls after FDA delays decision on thalassemia drug By Investing.com - Investing.com UK
Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia - The Manila Times
Agios (Nasdaq: AGIO) says FDA mitapivat thalassemia sNDA still under review after Dec. 7 PDUFA goal date - Stock Titan
(AGIO) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
Agios Faces A Make-Or-Break Year As Key Drug Decisions Loom - Finimize
How The Latest Trial And FDA Risk Shift The Story For Agios Pharmaceuticals - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC (AGIO) Investigation: Bronstei - The National Law Review
How Agios Pharmaceuticals Inc. (8AP) stock trades pre earningsMarket Movement Recap & Daily Profit Focused Stock Screening - Newser
Will Agios Pharmaceuticals Inc. (8AP) stock hit analyst forecasts2025 Support & Resistance & Fast Gaining Stock Reports - Newser
Why Agios Pharmaceuticals Inc. (8AP) stock stays on buy listsPortfolio Update Report & Growth Oriented Trading Recommendations - Newser
How analysts rate Agios Pharmaceuticals Inc. stock todayPortfolio Gains Report & Daily Technical Forecast Reports - Newser
Why Agios Pharmaceuticals Inc. (8AP) stock appears on watchlists2025 Historical Comparison & Real-Time Stock Entry Alerts - Newser
Why Agios Pharmaceuticals (AGIO) Is Down 7.1% After Phase 3 Sickle Cell Win With Mitapivat - Sahm
Europe Autoimmune Hemolytic Anemia Therapeutics Market to hit - openPR.com
How cyclical is Agios Pharmaceuticals Inc. (8AP) stock compared to rivalsJuly 2025 Opening Moves & Low Risk Investment Opportunities - Newser
Sickle Cell Disease Market is Predicted to Exhibit Remarkable Growth at a CAGR of 22.1% During the Forecast Period (2025–2034) Across 6MM, Owing to the Increasing Prevalence, Awareness, and Advancements in Gene Therapies | DelveInsight - GlobeNewswire Inc.
Fisher Asset Management LLC Sells 81,799 Shares of Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Is Agios Pharmaceuticals Inc. (8AP) stock a top dividend aristocrat candidateWeekly Trading Summary & Weekly Return Optimization Plans - Newser
Published on: 2025-12-03 01:52:18 - Newser
FDA’s docket holds 16 more PDUFA dates by year-end - BioCentury
Prudential Financial Inc. Lowers Holdings in Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
How Agios Pharmaceuticals Inc. (8AP) stock gains from tech spending2025 Breakouts & Breakdowns & Fast Entry and Exit Trade Plans - Newser
Agios Pharmaceuticals (AGIO) Upgraded After Mixed Sickle Cell Data and Pending Thalassemia Catalyst - MSN
How Agios Pharmaceuticals Inc. (8AP) stock moves on employment dataMarket Risk Summary & Growth Focused Investment Plans - Newser
Published on: 2025-12-02 00:03:25 - Newser
Is Agios Pharmaceuticals Inc a good long term investmentPortfolio Risk Assessment & Minimal Capital Trading Tips - earlytimes.in
Agios Pharmaceuticals (NASDAQ:AGIO) Upgraded by Citigroup to Strong-Buy Rating - MarketBeat
How Agios Pharmaceuticals Inc. stock reacts to Fed rate cutsJuly 2025 Chart Watch & Verified Stock Trade Ideas - BỘ NỘI VỤ
How Agios Pharmaceuticals Inc. stock valuations compare to rivals2025 Biggest Moves & Long Hold Capital Preservation Tips - BỘ NỘI VỤ
A Look at Agios Pharmaceuticals (AGIO) Valuation Following Strong Phase 3 Sickle Cell Trial Results - Sahm
Envestnet Asset Management Inc. Reduces Holdings in Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Aug Intraday: How strong is Agios Pharmaceuticals Inc. stock balance sheet2025 Fundamental Recap & AI Powered Buy and Sell Recommendations - moha.gov.vn
Agios Pharmaceuticals Inc Stock Analysis and ForecastDividend Aristocrats List & Trusted Financial Advisors at No Cost - earlytimes.in
Agios Pharmaceuticals Inc (AGIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Agios Pharmaceuticals Inc 주식 (AGIO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Scadden David | Director |
Nov 12 '25 |
Sale |
43.84 |
200 |
8,768 |
17,603 |
| Gheuens Sarah | Chief Medical Officer |
Nov 11 '25 |
Option Exercise |
25.01 |
2,454 |
61,375 |
64,181 |
| Gheuens Sarah | Chief Medical Officer |
Nov 11 '25 |
Sale |
43.78 |
2,454 |
107,436 |
61,727 |
1.08%
0.91%
자본화:
|
볼륨(24시간):